Systematic Review | Platinum doublet therapy outperforms non-platinum for advanced NSCLC, performance status 2 patients

Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status – Cochrane Library

Summary: Best therapy for people with advanced non-small cell lung cancer who have not been treated without a targetable mutation and moderately impaired performance status – Cochrane Library